PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting PERSIST-AVR is the first prospective, randomized, multi-center international trial comparing Perceval ...

The next-generation sutureless surgical technology is based on a clinically proven platform and designed for valve durability Perceval Plus is the next generation of Perceval, which is a trusted ...

LivaNova delivered new data from its sutureless aortic heart valve, showing fewer complications and stronger clinical outcomes compared to traditional implants built on a stent frame. An international ...

LivaNova is launching the Perceval Plus sutureless surgical aortic heart valve in Europe. The news comes after the company completed a one-year limited launch with initial real-world clinical data ...

LivaNova, PLC (the “Company”), a global medical technology company and a leader in the treatment of cardiovascular diseases, announced the first U.S. implantation of the Perceval valve, the sutureless ...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its Perceval ® sutureless aortic heart valve received ...

Over five million people are diagnosed with heart valve disease each year in the US, according to John Muir Health. Heart valve disease can occur in any valve or in some combination of the four valves ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus Standard-Aortic ...